drugset / Trial / NCT05737199
Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
Phase 2
Active not recruiting
21 enrolled
Niigata University Medical & Dental Hospital
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of MK-3475 in patients with ovarian squamous cell carcinoma.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2028-05-31
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |